Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Numbed Ink is a consumer healthcare company specializing in the development and distribution of high-strength topical anesthetics. The company's product line is primarily designed to mitigate pain associated with dermatological and cosmetic procedures such as tattooing, piercings, and microblading. Their flagship offering is a 5% lidocaine cream, which represents the maximum concentration allowed for over-the-counter use in many jurisdictions. The formulation is engineered for deep skin penetration and long-lasting desensitization to improve the patient and client experience during needle-based applications. Numbed Ink markets its products through direct-to-consumer channels and partnerships with professional studios. The company focuses on safety, efficacy, and ease of application within the aesthetic and body art industries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Numbed Ink.